denosumab   Click here for help

GtoPdb Ligand ID: 6886

Synonyms: AMG-162 | M05BX04 | Prolia® | Xgeva®
Approved drug
denosumab is an approved drug (FDA and EMA (2010))
Compound class: Antibody
Comment: Denosumab suppresses the activity of RANK ligand (RANKL), which normally promotes bone removal and resorption, but which becomes over active in many bone loss diseases.
Denosumab is produced from CHO cells stably expressing recombinant antibody component proteins [1]. It was the first RANKL inhibitor to be approved by the FDA.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
denosumab-bbdz; GP2411Jubbonti®; Wyost®SandozEMA & FDA (2024)Interchangeable with originator reference products Prolia® and Xgeva®
denosumab-dssb; SB16Ospomyv®; Xbryk®Samsung BioepisFDA (2025)As per originator reference products
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: denosumab

Classification Click here for help
Compound class Antibody
Approved drug? Yes. EMA (2010)  |  FDA (2010)
International Nonproprietary Names Click here for help
INN number INN
8653 denosumab
Synonyms Click here for help
AMG-162 | M05BX04 | Prolia® | Xgeva®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 249
Other databases
GtoPdb PubChem SID 178103468
PubChem SID 178103468
Search PubMed clinical trials denosumab
Search PubMed titles denosumab
Search PubMed titles/abstracts denosumab
Wikipedia Denosumab